Exploring The Mechanism Of Duhuo In Treating Rheumatoid Arthritis

Technical Summary: Exploring The Mechanism Of Duhuo In Treating Rheumatoid Arthritis

Problem Statement
Rheumatoid arthritis (RA) is a debilitating autoimmune disorder characterized by synovial hyperplasia, inflammatory cell infiltration, and progressive cartilage destruction. While current pharmacological interventions (NSAIDs, glucocorticoids, DMARDs, and biologics) alleviate symptoms, they are often limited by toxicity, high costs, infection risks, and metabolic side effects. Angelicae Pubescentis Radix (Duhuo), a traditional Chinese medicine (TCM) herb, has demonstrated efficacy in treating rheumatic pain and RA. However, its precise molecular mechanisms, particularly how its multi-component nature interacts with the complex pathogenesis of RA, remain incompletely understood. This study aims to elucidate the pharmacological basis and action mechanisms of Duhuo in treating RA.

Methodology
The study employed a multi-step approach integrating network pharmacology, molecular docking, and in vitro experimental validation:

1. Data Collection and Screening:
   • RA Targets: 6,705 RA-related genes were retrieved from GeneCards and DrugBank; 1,453 high-relevance targets (score ≥ 3.5) were retained.
   • Duhuo Constituents: Active constituents were screened from the TCMSP database using criteria of oral bioavailability (OB) ≥ 30% and drug-likeness (DL) ≥ 0.18.
   • Target Prediction: SwissTargetPrediction was used to identify potential targets for the screened constituents.
2. Network Construction and Analysis:
   • An intersection analysis identified 85 common genes between Duhuo constituents and RA targets.
   • A drug-component-target network was constructed using Cytoscape to visualize multi-constituent synergies and identify core targets based on degree values.
   • Enrichment Analysis: Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses were performed on the 85 intersecting genes using the DAVID database to identify biological processes, cellular components, molecular functions, and signaling pathways.
3. Molecular Docking:
   • The top three constituents (by degree value) were docked with core target proteins using AutoDock Tools. Binding affinities were evaluated via binding energy calculations and visualized using PyMOL.
4. In Vitro Validation:
   • Cell Model: TNF-α-induced MH7A human rheumatoid arthritis synovial fibroblast cells were used.
   • Treatments: Cells were treated with Duhuo extract at concentrations of 1 mg/mL and 4 mg/mL.
   • Assays:
     • Proliferation: Cell viability was assessed via CCK-8 assay at 24 and 48 hours.
     • Apoptosis: Flow cytometry (Annexin V-FITC/PI staining) was used to quantify early and late apoptosis rates after 48 hours.
     • Gene Expression: RT-qPCR was performed to measure the relative expression levels of target genes (JAK2, PIK3CA, PIK3CG).

Key Contributions and Results

• Identification of Active Constituents and Targets:

  • Nine potential active constituents were identified, including beta-sitosterol, nodakenin, O-Acetylcolumbianetin, and imperatorin.
  • The intersection analysis yielded 85 shared genes. Network topology analysis identified PIK3CA, PIK3CG, and JAK2 as core therapeutic targets.
  • GO enrichment highlighted biological processes such as protein phosphorylation, chromatin remodelling, and inflammatory response. KEGG analysis indicated significant enrichment in cancer pathways, PI3K/Akt signaling, EGFR signaling, and apoptosis regulation.

• Molecular Docking Validation:

  • Strong binding affinities were confirmed between specific constituents and core targets:
    • Imperatorin bound to PIK3CA (-6.5 kcal/mol).
    • Angelicone bound to JAK2 (-3.67 kcal/mol).
    • O-Acetylcolumbianetin bound to PIK3CG (-8.4 kcal/mol).

• Experimental Validation (MH7A Cells):

  • Anti-proliferative Effect: Duhuo extract inhibited MH7A cell proliferation in a dose- and time-dependent manner. Viability decreased by 34.5%–39.3% at 24 hours and 23.6%–48.9% at 48 hours compared to the TNF-α group.
  • Pro-apoptotic Effect: Flow cytometry revealed a significant increase in apoptosis rates. Total apoptosis increased by 285.8% (at 1 mg/mL) and 416.8% (at 4 mg/mL) compared to controls.
  • Gene Expression: RT-qPCR confirmed that Duhuo extract dose-dependently reduced the expression of target genes: JAK2 (27.1%–45.5% reduction), PIK3CG (13.1%–30.3% reduction), and PIK3CA (36.6%–46.8% reduction).

Significance and Claims
The paper claims to provide experimental evidence supporting the pharmacological basis of Duhuo in treating RA. The study concludes that the active constituents in Duhuo exert therapeutic effects by inhibiting the expression of the target genes JAK2, PIK3CA, and PIK3CG in RA-affected cells. Specifically:

• Angelicone acts on JAK2 to inhibit protein phosphorylation and tyrosine kinase activity.
• Imperatorin acts on PIK3CA to suppress PI3K/Akt signaling and EGFR signaling pathways.
• O-Acetylcolumbianetin acts on PIK3CG to modulate inflammatory responses and PI3K/Akt signaling.

By suppressing these pathways, Duhuo inhibits the proliferation of synovial fibroblasts and induces apoptosis, thereby addressing key pathological mechanisms of RA. The authors position these findings as a validation of the multi-component, multi-target mechanism of TCM, aligning network pharmacology predictions with in vitro biological outcomes.